{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:08:16Z","timestamp":1788890896012,"version":"build-2803163510"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019063","name":"Tandem Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Painful diabetic neuropathy (PDN) is a common complication of diabetes that leads to significant co-morbidity. Emerging evidence suggests glycaemic variability may be linked to fluctuations in pain intensity. Hybrid closed loop (HCL) systems reduce glycaemic variability, raising the possibility that they may modify pain intensity. This study aims to evaluate the effects of HCL use on pain intensity in people with PDN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>PAINLESS is a two-centre, randomised cross-over study, recruiting 49 adults with type 1 diabetes and PDN. Each participant will complete two 12-week intervention periods in a randomised sequence (1:1): one with standard care including continuous glucose monitoring (CGM) and one with HCL using the Tandem t:slim X2 insulin pump with Control-IQ technology. The primary outcome is the change in 7-day average 24-hour pain intensity [rated on a numerical scale from 0-10 (NRS)] from baseline to the end of each 12-week intervention period as measured by daily pain diaries. Secondary outcomes include measures of pain trajectory\/durability [responder rates (30% and 50% pain reduction in 7-day NRS), and the AUC for daily NRS scores], functional and quality of life outcomes [Short Form Health Survey (SF-36), and Short Form of the Brief Pain Inventory (BPI-MSF)], mood [Beck Depression Inventory (BDI)], health status [EQ-5D-5L], and global improvement [participant and clinician reported global impression of change]. Exploratory endpoints will harness neurophysiological assessments including Sudoscan, DPN-Check, Vagus and Vibrosense, and sleep and activity data from Withings devices. Statistical analyses will employ an intention-to-treat approach and mixed effect models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Timelines<\/jats:title>\n                    <jats:p>24-month trial: 18 months recruitment\/follow up, 6 months close-out, analyses and dissemination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Registration Details<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/ISRCTN24233750\" xlink:type=\"simple\">ISRCTN24233750<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0357573","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:32:06Z","timestamp":1788888726000},"page":"e0357573","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pain alleviation in diabetic neuropathy using hybrid closed loop insulin pumps (PAINLESS) \u2013 A randomised crossover trial protocol"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9100-8778","authenticated-orcid":true,"given":"Simon Alexander","family":"Berry","sequence":"first","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield","place":["Sheffield, United Kingdom"]},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Iqbal","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield","place":["Sheffield, United Kingdom"]},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Elliott","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3025-8703","authenticated-orcid":true,"given":"Abdul","family":"Paracha","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester","place":["Leicester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-8057","authenticated-orcid":true,"given":"Vaios","family":"Koutroukas","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester","place":["Leicester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2793-309X","authenticated-orcid":true,"given":"Mohummad Shaan","family":"Goonoo","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield","place":["Sheffield, United Kingdom"]},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor Fatima","family":"Haq","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3868-6388","authenticated-orcid":true,"given":"Andrew","family":"Gerges","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Sloan","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield","place":["Sheffield, United Kingdom"]},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Tesfaye","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield","place":["Sheffield, United Kingdom"]},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester","place":["Leicester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Selvarajah","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield","place":["Sheffield, United Kingdom"]},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"],"department":["Department of Diabetes and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"10","key":"pone.0357573.ref001","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","article-title":"Epidemiology of peripheral neuropathy and lower extremity disease in diabetes","volume":"19","author":"CW Hicks","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"5","key":"pone.0357573.ref002","doi-asserted-by":"crossref","DOI":"10.2174\/1573399817666210707112413","article-title":"The treatment of painful diabetic neuropathy","volume":"18","author":"G Sloan","year":"2022","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"pone.0357573.ref003","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/1479164114522135","article-title":"The contributors of emotional distress in painful diabetic neuropathy","volume":"11","author":"D Selvarajah","year":"2014","journal-title":"Diab Vasc Dis Res"},{"issue":"5","key":"pone.0357573.ref004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis","volume":"24","author":"N Soliman","year":"2025","journal-title":"Lancet Neurol"},{"issue":"10353","key":"pone.0357573.ref005","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","article-title":"Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial","volume":"400","author":"S Tesfaye","year":"2022","journal-title":"Lancet"},{"key":"pone.0357573.ref006","doi-asserted-by":"crossref","DOI":"10.23970\/AHRQEPCERTA218","volume-title":"The effectiveness and risks of long-term opioid treatment of chronic pain","author":"RA Chou","year":"2014"},{"issue":"1","key":"pone.0357573.ref007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s44158-024-00219-6","article-title":"Neuromodulation in chronic pain management: addressing persistent doubts in spinal cord stimulation","volume":"5","author":"G Lo Bianco","year":"2025","journal-title":"J Anesth Analg Crit Care"},{"issue":"5","key":"pone.0357573.ref008","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/jdi.13394","article-title":"Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy","volume":"12","author":"J Yang","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"1","key":"pone.0357573.ref009","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s42003-021-02896-3","article-title":"Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review","volume":"4","author":"X Zhang","year":"2021","journal-title":"Commun Biol"},{"issue":"12","key":"pone.0357573.ref010","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"T Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"pone.0357573.ref011","doi-asserted-by":"crossref","first-page":"111757","DOI":"10.1016\/j.diabres.2024.111757","article-title":"Diabetic peripheral neuropathy and glycemic variability assessed by continuous glucose monitoring: a systematic review and meta-analysis","volume":"213","author":"Y Jia","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"pone.0357573.ref012","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1464-5491.2002.00801.x","article-title":"The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study","volume":"19","author":"SO Oyibo","year":"2002","journal-title":"Diabet Med"},{"issue":"5","key":"pone.0357573.ref013","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s13300-023-01394-5","article-title":"A systematic review of commercial hybrid closed-loop automated insulin delivery systems","volume":"14","author":"S Peacock","year":"2023","journal-title":"Diabetes Therapy"},{"issue":"3","key":"pone.0357573.ref014","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/dia.2021.0319","article-title":"Safety and Glycemic Outcomes During the MiniMed\u2122 Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes","volume":"24","author":"AL Carlson","year":"2022","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"pone.0357573.ref015","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(22)00212-1","article-title":"Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study","volume":"10","author":"P Choudhary","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"pone.0357573.ref016","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"SA Brown","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"pone.0357573.ref017","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2337\/dc21-0172","article-title":"Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes","volume":"44","author":"SA Brown","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"pone.0357573.ref018","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.pain.2012.03.003","article-title":"Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations","volume":"153","author":"RH Dworkin","year":"2012","journal-title":"Pain"},{"key":"pone.0357573.ref019","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomised trials","volume":"389","author":"A-W Chan","year":"2025","journal-title":"BMJ"},{"issue":"10","key":"pone.0357573.ref020","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S1474-4422(22)00188-0","article-title":"Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments","volume":"21","author":"MA Elafros","year":"2022","journal-title":"Lancet Neurol"},{"key":"pone.0357573.ref021","unstructured":"National Institute for Health and Care Excellence (NICE). QS208: Type 1 diabetes. 2023."},{"key":"pone.0357573.ref022","volume-title":"Dexcom G7 User Guide","author":"Dexcom Inc","year":"2024"},{"key":"pone.0357573.ref023","unstructured":"Tandem Diabetes Care Inc. t:slim X2 insulin pump user guide. 2024."},{"key":"pone.0357573.ref024","doi-asserted-by":"crossref","DOI":"10.1002\/acr.20543","article-title":"Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)","volume":"63","author":"GA Hawker","year":"2011","journal-title":"Arthritis Care & Research (Hoboken)"},{"key":"pone.0357573.ref025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2377-9-6","article-title":"Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain","volume":"9","author":"S Quilici","year":"2009","journal-title":"BMC Neurol"},{"key":"pone.0357573.ref026","unstructured":"European Medicines Agency. Guideline on the clinical development of medicinal products intended for the treatment of pain 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-development-medicinal-products-intended-treatment-pain-first-version_en.pdf"},{"issue":"4","key":"pone.0357573.ref027","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial","volume":"6","author":"RW Richter","year":"2005","journal-title":"J Pain"},{"key":"pone.0357573.ref028","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","article-title":"Duloxetine vs. placebo in patients with painful diabetic neuropathy","volume":"116","author":"DJ Goldstein","year":"2005","journal-title":"Pain"},{"issue":"1","key":"pone.0357573.ref029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"SJ Pocock","year":"1975","journal-title":"Biometrics"},{"issue":"7","key":"pone.0357573.ref030","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/dme.13630","article-title":"One-stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high-risk foot","volume":"35","author":"O Binns-Hall","year":"2018","journal-title":"Diabet Med"},{"issue":"12","key":"pone.0357573.ref031","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S2213-8587(19)30081-6","article-title":"Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention","volume":"7","author":"D Selvarajah","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"pone.0357573.ref032","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/dia.2015.0396","article-title":"Normative values for electrochemical skin conductances and impact of ethnicity on quantitative assessment of sudomotor function","volume":"18","author":"AI Vinik","year":"2016","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"pone.0357573.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249461","article-title":"Normative values of the vibration perception thresholds at finger pulps and metatarsal heads in healthy adults","volume":"16","author":"L Ekman","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"pone.0357573.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212921","article-title":"Strong association between vibration perception thresholds at low frequencies (4 and 8 Hz), neuropathic symptoms and diabetic foot ulcers","volume":"14","author":"E Lindholm","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"pone.0357573.ref035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10286-024-01069-6","article-title":"Normative data on measures of cardiovascular autonomic neuropathy and the effect of pretest conditions in a large Danish non-diabetic CVD-free population from the Lolland-Falster Health Study","volume":"35","author":"CS Hansen","year":"2024","journal-title":"Clin Auton Res"},{"key":"pone.0357573.ref036","unstructured":"National Insitute for Health and Care Excellence (NICE). TA943: Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. 2023."},{"key":"pone.0357573.ref037","unstructured":"NHS England. Hybrid closed loop technologies: 5-year implementation strategy 2024. https:\/\/www.england.nhs.uk\/long-read\/hybrid-closed-loop-technologies-5-year-implementation-strategy\/"},{"key":"pone.0357573.ref038","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/brain\/awu307","article-title":"Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes","volume":"138","author":"CH Gibbons","year":"2015","journal-title":"Brain"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:32:15Z","timestamp":1788888735000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357573"}},"subtitle":[],"editor":[{"given":"Yee Gary","family":"Ang","sequence":"first","affiliation":[{"name":"National Healthcare Group","place":["SINGAPORE"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357573","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}